Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TYMS | P04818 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12820641 | 0.84 | MEN1 (0.57) | MAPTHPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12820639 | 0.84 | MAOB (0.52) | MAPTCTSBHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL12820638 | 0.84 | SCN9A (0.56) | MAPTHPGDSMN1; SMN2DAOALDH1A1 | |
| SCHEMBL12820629 | 0.72 | KDM4E (0.42) | KDM4EALDH1A1 | |
| SCHEMBL25932075 | 0.72 | KDM4E (0.45) | TP53MAPTCTSBSMN1; SMN2DAO | |
| SCHEMBL12820642 | 0.70 | HSD17B10 (0.43) | MAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12820579 | 0.70 | HTT (0.46) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL12820769 | 0.69 | ALDH1A1 (0.47) | MAPTHPGDMEN1KMT2AKDM4E | |
| SCHEMBL10007309 | 0.67 | KDM4E (0.49) | TP53MAPTL3MBTL1TYMSKDM4E | |
| SCHEMBL12820575 | 0.67 | MEN1 (0.45) | MAPTSMN1; SMN2MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252791-A1 | Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain | CHILDREN'S MEDICAL CENTER CORPORATION | 2012-10-04 | — | — | US | disclosed |
| US-20120252791-A1 | Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain | CHILDREN'S MEDICAL CENTER CORPORATION | 2012-10-04 | — | — | US | disclosed |
| WO-2011035009-A1 | HETEROCYCLIC GTP CYCLOHYDROLASE 1 INHIBITORS FOR THE TREATMENT OF PAIN | HERCULES TECHNOLOGY MANAGEMENT CO V, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252791-A1 | Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain | GGH, GGPS1, GGT1 | TP53 3877/4885MAPT 291/4885CTSB 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.